KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Current Liabilities (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Total Current Liabilities data on record, last reported at $94.4 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 73.81% year-over-year to $94.4 million; the TTM value through Sep 2025 reached $94.4 million, up 73.81%, while the annual FY2024 figure was $63.3 million, 18.83% up from the prior year.
  • Total Current Liabilities reached $94.4 million in Q3 2025 per RIGL's latest filing, up from $86.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $94.4 million in Q3 2025 and bottomed at $44.0 million in Q2 2023.
  • Average Total Current Liabilities over 5 years is $60.5 million, with a median of $59.2 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: decreased 23.14% in 2023, then skyrocketed 73.81% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $63.6 million in 2021, then grew by 2.61% to $65.2 million in 2022, then decreased by 18.32% to $53.3 million in 2023, then grew by 18.83% to $63.3 million in 2024, then soared by 49.13% to $94.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $94.4 million in Q3 2025, $86.6 million in Q2 2025, and $66.6 million in Q1 2025.